The nuclear receptor corepressor 2 (NCOR2), also known as SMRT (silencing mediator for retinoid and thyroid hormone receptors), is a transcriptional coregulator involved in gene silencing. It functions by forming complexes with nuclear receptors (e.g., thyroid hormone, estrogen, or retinoic acid receptors) and chromatin-modifying enzymes like histone deacetylases (HDACs), thereby repressing target gene transcription. NCOR2 plays critical roles in development, metabolism, and cellular differentiation, and its dysregulation has been implicated in cancers, metabolic disorders, and neurodegenerative diseases.
Antibodies targeting NCOR2 are essential tools for studying its expression, localization, and interactions in various biological contexts. They are widely used in techniques such as Western blotting, immunoprecipitation, chromatin immunoprecipitation (ChIP), and immunofluorescence to investigate NCOR2's regulatory mechanisms. These antibodies help identify NCOR2's involvement in pathways like hormone signaling, inflammation, and oncogenesis. For instance, altered NCOR2 expression or mutations have been linked to therapy resistance in breast/prostate cancers and defects in lipid metabolism. Validated NCOR2 antibodies are critical for ensuring specificity in detecting its isoforms (~120-150 kDa) and distinguishing it from related corepressors like NCOR1. Their applications extend to both basic research and clinical studies exploring transcriptional repression dynamics.